Company: SRPT
Filing Date: 2025-04-24
Form Type: DEF 14A
Source: 0000950170-25-058003
Chunk: 44

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-04-24
Form: DEF 14A
Chunk 44
---
 of the Company and help us to attract, retain and motivate people whose skills and performance are critical to our success in our industry’s very competitive labor markets. By granting "at-risk" equity awards, we further align the interests of our service providers with those of our stockholders. Failure to obtain stockholder approval to approve the amendment to the 2018 Plan and increase the share reserve under the 2018 Plan, which currently is insufficient to cover projected needs over the next year, could have a negative impact on the Company and its ability to retain and motivate key employees, consultants and advisors and, therefore, negatively impact the Company’s ability to effectively execute its business plans. Vote Required and Board Recommendation The affirmative vote of a majority of the votes cast is required to approve this proposal, excluding abstentions and broker non-votes. The Board recommends that stockholders vote “FOR” approval of the amendment to the 2018 Plan. THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK.

<div align='center'>25

VOTE TO APPROVE AN AMENDMENT TO THE 2016 ESPP

(Proposal 4)</div>

Stockholders are being asked to approve an amendment ("Amendment No. 3") to the Company's Amended and Restated 2013 Employee Stock Purchase Plan (as Amended and Restated as of June 27, 2016) (the "2016 ESPP"). Amendment No. 3 was adopted by the Board on April 11, 2025 and will become effective upon receiving stockholder approval at our Annual Meeting. The 2016 ESPP was originally adopted by the Board on April 16, 2013, approved by our stockholders on June 4, 2013, amended and restated by the Board on May 6, 2016, and approved by our stockholders on June 27, 2016, and then further amended by the Board effective April 22, 2019 and approved by our stockholders on June 6, 2019, and again amended by the Board on April 6, 2023 and approved by our stockholders on June 8, 2023.

The purpose of Amendment No. 3 is to increase the number of shares of our common stock authorized for issuance under the 2016 Plan by 300,000 shares so that eligible employees of the Company and certain of its subsidiaries can continue to acquire a stock ownership interest in the Company pursuant to a plan that is intended